Drug Profile
Methionine enkephalin - Biostax
Alternative Names: CYTO-401; INNO-105; IRT-101; IRT-102; MENK; Menkophian; Met-enkephalin; OGF; Opioid growth factor; Proenkephalin; STAT 400; STAT-401Latest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Developer Biostax; Hubei Qianjiang Pharmaceutical; Penn State College of Medicine; Statera BioPharma
- Class Antineoplastics; Antivirals; Enkephalins; Essential amino acids; Opioid peptides; Small molecules
- Mechanism of Action Immunostimulants; Opioid growth factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II HIV infections; Liver cancer; Ovarian cancer; Pancreatic cancer
- No development reported Solid tumours
- Discontinued COVID 2019 infections; Influenza A virus H1N1 subtype; Influenza virus infections; Thyroid cancer
Most Recent Events
- 20 Apr 2023 Statera Biopharma amends royalty-bearing license agreement with Biostax for the rights to methionine enkephalin
- 26 Sep 2022 Discontinued - Phase-II for COVID-2019 infections (unspecified route)
- 26 Sep 2022 Discontinued - Phase-II for Influenza A virus H1N1 subtype (Intranasal)